David Mutch
Gynecologic Oncology · Saint Louis, MONPI 1518985217
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Clovis Oncology, Inc. at 37.0% of the total. Reporting peaked in 2019 at $17,785 and has fallen 98.8% since, to $219 in 2025.
Across 67 payments — averaging $383.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Clovis Oncology, Inc.$10K
- AstraZeneca$8K
- GSK$6K
- Merck$1K
- Intuitive Surgical$300
- Eisai Inc.$227
- plus $652 from 10 others
Across 176 payments — averaging $23,063 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$2.9M
- F. Hoffmann-la Roche AG$821K
- Roche Products Limited$136K
- AstraZeneca$77K
- Exelixis Inc.$64K
- EMD Serono, Inc.$26K
- plus $34K from 2 others
What the payments were for
- Consulting fees$10,20840%
- Speaking & faculty fees$12,10047%
- Travel & lodging$1,3275%
- Food & beverage$2,0358%
- Education$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Clovis Oncology, Inc. | 16 | $9,510 |
| AstraZeneca | 8 | $7,970 |
| GSK | 7 | $5,886 |
| Merck | 8 | $1,148 |
| Intuitive Surgical | 4 | $300 |
| Eisai Inc. | 4 | $227 |
| Myriad Genetic Laboratories, Inc. | 1 | $142 |
| Genentech USA, Inc. | 1 | $127 |
| Corcept Therapeutics | 1 | $119 |
| AbbVie | 7 | $112 |
| Amgen | 3 | $48 |
| Organon | 2 | $33 |
| Therapeuticsmd, Inc. | 2 | $24 |
| Coopersurgical, Inc. | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Scynexis, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,693 in reported general payments places this provider in the 85th percentile of 38 gynecologic oncology providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PremarinEstrogens, Conjugated | 19 | $7,163 |
| PremproEstrogen,con/M-Progest Acet | 11 | $2,620 |
| Estradiol | 41 | $1,202 |
| Letrozole | 12 | $543 |
| Gabapentin | 14 | $164 |
| Pantoprazole Sodium | 11 | $147 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Saint Louis
- Premal ThakerSaint Louis$287K
- Matthew PowellSaint Louis$162K
- Dan-Arin SilasiSaint Louis$23K
- Dineo KhabeleSaint Louis$22K
- Carolyn McCourtSaint Louis$14K
- Andrea HagemannSaint Louis$11K
- Shannon GraboschSaint Louis$9K
- Randall GibbSaint Louis$8K
- Leslie MassadSaint Louis$6K
- Madhavi ManyamSaint Louis$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.